Short answer
ArriVent BioPharma, Inc. (AVBP) filed its Q3 2025 10-Q quarterly report on Nov 10, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$35M
- −70.1% YoY · −11.4% QoQ
- EPS (diluted)
- −$0.76
- −24.6% YoY · +13.6% QoQ
Source: XBRL data from the ArriVent BioPharma, Inc. (AVBP) Q3 2025 10-Q on SEC EDGAR. USD.
ArriVent BioPharma, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $0; no product sales or other revenue generated
- Operating margin not applicable; operating loss $38.3M vs $24.2M YoY
- R&D highest: FURVENT $13.8M, up $4.9M; lowest: FAVOUR $0.3M
- Cash, equivalents and marketable securities $305.4M at September 30, 2025
- Capital deployment: $80.6M July offering proceeds; $40.0M Lepu upfront payment expensed year-to-date
Risk Factors
- No risk-factors section provided; submitted text covers Items 2–6
- No unregistered securities sales during the quarter
- IPO proceeds $183.2 million with no material change in planned use
- No director or executive Rule 10b5-1 plan activity during the quarter
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ArriVent BioPharma, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.